D.E. Shaw & Co
PRAX icon

D.E. Shaw & Co’s Praxis Precision Medicines PRAX Stock Holding History

D.E. Shaw & Co’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,000
Closed -$1.47M – 4949
2025
Q4 		$1.47M Buy
+5,000
New +$931K ﹤0.01% 3280

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

D.E. Shaw & Co's PRAX Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 5,140 shares worth $1.72M. The stake represents ﹤0.01% of the portfolio and ranks #3334 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in PRAX as recently as Q4 2025.

D.E. Shaw & Co first reported a position in PRAX in Q2 2021 and has held it in 12 quarters since. The position peaked at $11M in Q4 2025. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • D.E. Shaw & Co held 5,140 shares of Praxis Precision Medicines worth $1.72M as of Q2 2026.
  • Praxis Precision Medicines was a new D.E. Shaw & Co position in Q2 2026.
  • Praxis Precision Medicines made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3334 holding.
  • D.E. Shaw & Co first reported a position in Praxis Precision Medicines in Q2 2021 and has held it in 12 quarters since.
  • D.E. Shaw & Co's Praxis Precision Medicines position peaked at $11M in Q4 2025.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.